Drug intelligence / Profile preview

trilobatin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Trilobatin is a natural dihydrochalcone glucoside, chemically described as phloretin with a β-D-glucopyranosyl at the 4' position; it occurs in the leaves of Lithocarpus polystachyus (Chinese “sweet tea”) and functions as a sweetening plant metabolite with reported antioxidant and anti‑inflammatory activities[1][8]. Preclinical studies report biological effects including improvement of DSS-induced colitis via suppression of NF‑κB signaling and modulation of gut microbiota in mice[3], regulation of glucose metabolism and insulin resistance through PI3K/Akt/GSK‑3β and Nrf2/Keap‑1 pathways in cell and STZ-mouse models[4], neuroprotection and cognitive benefit in Alzheimer’s disease models via direct binding to HMGB1 and activation of SIRT3/SOD2 signaling[6], and antidepressant-like effects in CUMS mice with identification as a naturally occurring GPR158 ligand[9][7]. It is available as a research chemical; there is no evidence of clinical approval as a pharmaceutical drug[8].

Other names
phloretin-4'-O-glucosidephloretin 4'-glucosidep-phlorizinp-phloridzin1-[4-(β-D-glucopyranosyloxy)-2,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one3,5-dihydroxy-4-[3-(4-hydroxyphenyl)propanoyl]phenyl β-D-glucopyranosideCAS 4192-90-9CAS4192-90-9CAS-4192-90-9
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)GPR158 (G protein-coupled receptor 158)GSK3 (Glycogen synthase kinase 3 beta)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)HMGB1 (High mobility group protein B1)KEAP1 (Kelch-like ECH-associated protein 1)NF-κBNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)SIRT3 (NAD-dependent protein deacetylase sirtuin-3)

Beyond the preview

Go deeper on trilobatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trilobatin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call